HomeSCNI • NASDAQ
add
Scinai Immunotherapeutics Ltd - ADR
Previous close
$3.85
Day range
$3.50 - $4.01
Year range
$2.34 - $9.30
Market cap
3.05M USD
Avg Volume
36.10K
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 284.00K | — |
Operating expense | 1.86M | -28.21% |
Net income | -2.32M | 38.28% |
Net profit margin | -817.61 | — |
Earnings per share | — | — |
EBITDA | -1.53M | 37.46% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.08M | -59.02% |
Total assets | 14.85M | -25.36% |
Total liabilities | 22.14M | -18.05% |
Total equity | -7.28M | — |
Shares outstanding | 837.36K | — |
Price to book | -0.44 | — |
Return on assets | -31.77% | — |
Return on capital | -34.88% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -2.32M | 38.28% |
Cash from operations | -1.76M | 38.87% |
Cash from investing | -6.00K | 98.41% |
Cash from financing | 12.00K | — |
Net change in cash | -1.87M | 43.14% |
Free cash flow | -1.20M | 60.77% |
About
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
Founded
Jan 1, 2003
Website
Employees
31
